Esperion Therapeutics (ESPR) Q2 2024 earnings summary

Executive summary

• Q2 2024 total revenue rose 186% year-over-year to $73.8M–$74M, with US net product revenue up 39% to $28.3M, driven by expanded labels and payer access for Nexletol and Nexlizet.

• Monetized European royalties for $304.7M, using proceeds to pay off and terminate the Oberland Capital facility, significantly improving liquidity and financial flexibility.

• Collaboration revenue surged 727% year-over-year to $45.4M–$45.5M, primarily from international partnerships, milestones, and the DSE settlement.

• Expanded addressable market to 70M US patients with new label approvals, including primary prevention and statin-intolerant populations.

• International launches and regulatory progress in Europe, Japan, Canada, Australia, and Israel are expected to drive future growth.

Financial highlights

• Q2 2024 total revenue: $73.8M–$74M (up 186% YoY); US net product revenue: $28.3M (up 39% YoY); collaboration revenue: $45.4M–$45.5M (up 727% YoY).

• R&D expenses decreased 48% YoY to $11.5M; SG&A expenses rose 30% YoY to $44.2M.

• One-time $53.2M loss on debt extinguishment; net loss for Q2 was $61.9M, or $0.33 per share, improved from $0.46 in Q2 2023.

• Cash and cash equivalents at June 30, 2024: $189.3M, up from $82.2M at year-end 2023.

• Operating expenses for Q2 2024: $71.3M; H1 2024: $136.7M.

Outlook and guidance

• Full-year 2024 operating expense guidance reiterated at $225M–$245M, including $20M in non-cash stock compensation.

• Anticipates continued US and international growth with expanded labels, payer coverage, and new launches.

• Management expects continued operating losses as commercialization and R&D activities persist; current cash and revenue expected to fund operations for the foreseeable future.